The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis.

Eur J Med Res · 2024 · PMC10768288 · PMID 38183123

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.00001actually significant

However, there was a highly significant decrease in the number of COVID-19 infections favored by the Evusheld 600 mg dose group over the other group ( p < 0.00001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.